Furthermore, they demonstrated that in a syngeneic mouse model of HNSCC, concurrent use of cisplatin and anti–PD-L1/PD-1 delayed tumor growth and enhanced survival without significantly reducing the number or function of tumor-infiltrating immune cells or increasing cisplatin-induced toxicities [48]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.